Shares of Insmed Incorporated (INSM) plummeted over 6% in pre-market trading on Thursday, after the biopharmaceutical company reported weaker-than-expected earnings for the third quarter of 2024 and provided a disappointing outlook.
For Q3, Insmed posted a loss of $1.27 per share, missing analysts' consensus estimate of $1.21 per share. The company's revenue of $93.4 million beat expectations of $93.3 million, driven by sales of its flagship drug Arikayce for the treatment of a rare lung disease.
However, Insmed reiterated its full-year 2024 guidance for global Arikayce revenues of $340 million to $360 million, which fell short of analysts' projections. The company also announced a new $150 million senior secured term loan tranche, raising concerns about its financial position and cash burn.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.